Key result
18F-FDG PET/MRI outperforms MRI alone in staging adult sarcomas, yielding ~96% sensitivity for local recurrences.
Why the study?
The clinical utility of 18F-FDG PET/MRI in adult patients with sarcomas for staging, restaging, and treatment response assessment requires summarization and clarification.
Does 18F-FDG PET/MRI improve staging, restaging, and treatment response assessment in adult patients with sarcomas compared to conventional imaging?
Does 18F-FDG PET/MRI improve staging, restaging, and treatment response assessment in adult patients with sarcomas compared to conventional imaging?
18F-FDG PET/MRI shows promise for improving staging, surgical margin delineation, and recurrence detection in adult sarcomas, including cardiac masses.
No takes yet. Share an insight, caveat, or question.
PET/MRI utility in sarcomas remains undefined; leaves open need for prospective trials before clinical adoption.
Cassarino et al. (2020) conducted a review in Adult sarcomas (n=154). 18F-FDG PET/MRI vs. Conventional imaging (MRI or CT) was evaluated on Diagnostic performance (sensitivity, specificity, accuracy). 18F-FDG PET/MRI demonstrated high diagnostic accuracy in adult sarcomas, showing superior sensitivity compared to MRI alone for detecting local recurrences (96.3% vs 81.5%) and distant metastases (97.8% vs 94.4%).